158 related articles for article (PubMed ID: 32145404)
1. Response of omalizumab in normocomplementemic urticarial vasculitis.
Chen YD; Krause K; Tu P; Zhao ZT; Maurer M
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2114-2117.e2. PubMed ID: 32145404
[No Abstract] [Full Text] [Related]
2. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
Rattananukrom T; Svetvilas P; Chanprapaph K
Asian Pac J Allergy Immunol; 2020 Dec; 38(4):286-289. PubMed ID: 30660172
[TBL] [Abstract][Full Text] [Related]
3. Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis.
Navarro-Navarro I; Jiménez-Gallo D; Villegas-Romero I; Linares-Barrios M
Dermatol Ther; 2020 Mar; 33(2):e13237. PubMed ID: 32012397
[No Abstract] [Full Text] [Related]
4. Urticarial Vasculitis Successfully Treated With Omalizumab.
Ermertcan AT; Aktaş A; Öztürk F; Temiz P
Cutis; 2021 May; 107(5):E19-E21. PubMed ID: 34288864
[No Abstract] [Full Text] [Related]
5. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
[TBL] [Abstract][Full Text] [Related]
6. Cold urticarial vasculitis successfully treated with omalizumab.
Ayén-Rodríguez A; Llamas-Molina JM; Gálvez-Moreno M; Ruiz-Villaverde R
Int J Dermatol; 2023 Feb; 62(2):e77-e78. PubMed ID: 35167707
[No Abstract] [Full Text] [Related]
7. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration.
Ito T; Maeda T; Egusa C; Abe N; Seshimo H; Okubo Y; Harada K
Allergol Int; 2021 Apr; 70(2):269-270. PubMed ID: 33183981
[No Abstract] [Full Text] [Related]
9. Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature.
Degirmentepe EN; Kızıltac K; Etikan P; Singer R; Memet B; Kocaturk E
Ann Dermatol; 2019 Jun; 31(3):335-338. PubMed ID: 33911601
[TBL] [Abstract][Full Text] [Related]
10. Refractory Normocomplementemic Urticarial Vasculitis Showing a Good Response to B-Cell Depletion Therapy.
Adwan M; Hanbali R; Farah RI
J Clin Rheumatol; 2021 Dec; 27(8S):S474-S475. PubMed ID: 31743269
[No Abstract] [Full Text] [Related]
11. Long-Term Efficacy and Safety of Omalizumab Monotherapy in a Patient With Normocomplementemic Urticarial Vasculitis.
Abuzakouk M; Ghorab O; Namas R; Maurer M
J Drugs Dermatol; 2022 Oct; 21(10):1124-1126. PubMed ID: 36219045
[TBL] [Abstract][Full Text] [Related]
12. Normocomplementemic urticarial vasculitis secondary to Lyme disease: A rare association with challenging treatment.
Teles C; Gaspar E; Gonçalo M; Santos L
J R Coll Physicians Edinb; 2023 Mar; 53(1):27-29. PubMed ID: 36519641
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Hypocomplementemic Urticarial Vasculitis With Omalizumab: A Case Report.
Pérez Codesido S; Rosado Ingelmo A; Gómez de la Fuente E; García García E; Privitera Torres M; Tejedor Alonso MA
J Investig Allergol Clin Immunol; 2020 Jun; 30(3):211-212. PubMed ID: 32571766
[No Abstract] [Full Text] [Related]
14. Normocomplementemic urticarial vasculitis in a young female with persistent joint pain.
Haque EK; Zaayman M; DeCrescenzo A; Menter A
Int J Dermatol; 2023 Jan; 62(1):e25-e27. PubMed ID: 34865228
[No Abstract] [Full Text] [Related]
15. Urticarial vasculitis: a unique presentation.
Stigall LE; Sigmon JR; Leicht SS
South Med J; 2009 May; 102(5):531-3. PubMed ID: 19373142
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis.
Davis MD; Daoud MS; Kirby B; Gibson LE; Rogers RS
J Am Acad Dermatol; 1998 Jun; 38(6 Pt 1):899-905. PubMed ID: 9631995
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome.
Aurich S; Simon JC; Treudler R
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e395-e397. PubMed ID: 28273376
[No Abstract] [Full Text] [Related]
18. Pulmonary hemosiderosis with normocomplementemic urticarial vasculitis in a child.
Yuksel H; Yilmaz O; Savas R; Kirmaz C; Sogut A; Ozalp S
Monaldi Arch Chest Dis; 2007 Mar; 67(1):63-6. PubMed ID: 17564286
[TBL] [Abstract][Full Text] [Related]
19. Urticarial vasculitis treated with colchicine.
Wiles JC; Hansen RC; Lynch PJ
Arch Dermatol; 1985 Jun; 121(6):802-5. PubMed ID: 4004306
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis.
Liu T; Bai J; Ying S; Li S; Pan Y; Fang D; Qiao J; Fang H
J Asthma Allergy; 2021; 14():433-437. PubMed ID: 33935505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
